Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases network.
Diagnosis
Omics
Ontology
Rare diseases
Undiagnosed
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
14 Sep 2020
14 Sep 2020
Historique:
received:
14
01
2020
accepted:
17
08
2020
entrez:
15
9
2020
pubmed:
16
9
2020
medline:
26
8
2021
Statut:
epublish
Résumé
For a number of persons with rare diseases (RDs) a definite diagnosis remains undiscovered with relevant physical, psychological and social consequences. Undiagnosed RDs (URDs) require other than specialised clinical centres, outstanding molecular investigations, common protocols and dedicated actions at national and international levels; thus, many "Undiagnosed RDs programs" have been gradually developed on the grounds of a well-structured multidisciplinary approach. The Italian Undiagnosed Rare Diseases Network (IURDN) was established in 2016 to improve the level of diagnosis of persons with URD living in Italy. Six Italian Centres of Expertise represented the network. The National Centre for Rare Diseases at the Istituto Superiore di Sanità coordinates the whole project. The software PhenoTips was used to collect the information of the clinical cases. One hundred and ten cases were analysed between March 2016 and June 2019. The age of onset of the diseases ranged from prenatal age to 51 years. Conditions were predominantly sporadic; almost all patients had multiple organs involvements. A total of 13/71 family cases were characterized by WES; in some families more than one individual was affected, so leading to 20/71 individuals investigated. Disease causing variants were identified in two cases and were associated to previously undescribed phenotypes. In 5 cases, new candidate genes were identified, although confirmatory tests are pending. In three families, investigations were not completed due to the scarce compliance of members and molecular investigations were temporary suspended. Finally, three cases (one familial) remain still unsolved. Twelve undiagnosed clinical cases were then selected to be shared at International level through PhenomeCentral in accordance to the UDNI statement. Our results showed a molecular diagnostic yield of 53,8%; this value is comparable to the diagnostic rates reported in other international studies. Cases collected were also pooled with those collected by UDNI International Network. This represents a unique example of global initiative aimed at sharing and validating knowledge and experience in this field. IURDN is a multidisciplinary and useful initiative linking National and International efforts aimed at making timely and appropriate diagnoses in RD patients who still do not have a confirmed diagnosis even after a long time.
Sections du résumé
BACKGROUND
BACKGROUND
For a number of persons with rare diseases (RDs) a definite diagnosis remains undiscovered with relevant physical, psychological and social consequences. Undiagnosed RDs (URDs) require other than specialised clinical centres, outstanding molecular investigations, common protocols and dedicated actions at national and international levels; thus, many "Undiagnosed RDs programs" have been gradually developed on the grounds of a well-structured multidisciplinary approach.
METHODS
METHODS
The Italian Undiagnosed Rare Diseases Network (IURDN) was established in 2016 to improve the level of diagnosis of persons with URD living in Italy. Six Italian Centres of Expertise represented the network. The National Centre for Rare Diseases at the Istituto Superiore di Sanità coordinates the whole project. The software PhenoTips was used to collect the information of the clinical cases.
RESULTS
RESULTS
One hundred and ten cases were analysed between March 2016 and June 2019. The age of onset of the diseases ranged from prenatal age to 51 years. Conditions were predominantly sporadic; almost all patients had multiple organs involvements. A total of 13/71 family cases were characterized by WES; in some families more than one individual was affected, so leading to 20/71 individuals investigated. Disease causing variants were identified in two cases and were associated to previously undescribed phenotypes. In 5 cases, new candidate genes were identified, although confirmatory tests are pending. In three families, investigations were not completed due to the scarce compliance of members and molecular investigations were temporary suspended. Finally, three cases (one familial) remain still unsolved. Twelve undiagnosed clinical cases were then selected to be shared at International level through PhenomeCentral in accordance to the UDNI statement.
CONCLUSIONS
CONCLUSIONS
Our results showed a molecular diagnostic yield of 53,8%; this value is comparable to the diagnostic rates reported in other international studies. Cases collected were also pooled with those collected by UDNI International Network. This represents a unique example of global initiative aimed at sharing and validating knowledge and experience in this field. IURDN is a multidisciplinary and useful initiative linking National and International efforts aimed at making timely and appropriate diagnoses in RD patients who still do not have a confirmed diagnosis even after a long time.
Identifiants
pubmed: 32928283
doi: 10.1186/s13052-020-00883-8
pii: 10.1186/s13052-020-00883-8
pmc: PMC7488856
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Subventions
Organisme : Ministero degli Affari Esteri e della Cooperazione Internazionale
ID : PGR00229, 2016-19
Références
Eur J Hum Genet. 2013 Feb;21(2):229-32
pubmed: 22549410
Genet Med. 2015 Jul;17(7):578-86
pubmed: 25356970
Am J Med Genet. 1997 Nov 28;73(1):1-4
pubmed: 9375913
Mol Genet Metab. 2012 Nov;107(3):403-8
pubmed: 23010432
Bioinformatics. 2009 Aug 1;25(15):1966-7
pubmed: 19497933
JAMA. 2014 Nov 12;312(18):1870-9
pubmed: 25326635
Int J Environ Res Public Health. 2018 Sep 21;15(10):
pubmed: 30248891
N Engl J Med. 2011 Nov 3;365(18):1663-72
pubmed: 22047557
Mol Genet Metab. 2020 Apr;129(4):243-254
pubmed: 32033911
Hum Mutat. 2012 May;33(5):777-80
pubmed: 22504886
JAMA Pediatr. 2017 Dec 4;171(12):e173438
pubmed: 28973083
Curr Protoc Hum Genet. 2019 Sep;103(1):e92
pubmed: 31479590
Am J Med Genet A. 2012 Jan;158A(1):10-2
pubmed: 22147492
Genet Med. 2016 Nov;18(11):1090-1096
pubmed: 26938784
J Genet Couns. 2018 Aug;27(4):935-946
pubmed: 29297108
J Pediatr Genet. 2017 Jun;6(2):61-76
pubmed: 28496993
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nucleic Acids Res. 2015 Jan;43(Database issue):D789-98
pubmed: 25428349
Adv Exp Med Biol. 2017;1031:301-322
pubmed: 29214580
Ital J Pediatr. 2017 Nov 3;43(1):100
pubmed: 29100554
Eur J Hum Genet. 2018 Sep;26(9):1266-1271
pubmed: 29891882
NPJ Genom Med. 2018 Apr 4;3:10
pubmed: 29644095
Nature. 2017 Aug 9;548(7666):158
pubmed: 28796211
Genet Med. 2016 Jul;18(7):696-704
pubmed: 26633542
Int J Environ Res Public Health. 2018 Aug 14;15(8):
pubmed: 30110963
J Clin Invest. 2016 Jan;126(1):239-53
pubmed: 26642364
Lancet. 2019 Aug 10;394(10197):533-540
pubmed: 31395441
Curr Opin Pediatr. 2014 Dec;26(6):626-33
pubmed: 25313974
N Engl J Med. 2018 Nov 29;379(22):2131-2139
pubmed: 30304647
Adv Exp Med Biol. 2017;1031:25-38
pubmed: 29214564
Hum Mutat. 2015 Oct;36(10):931-40
pubmed: 26251998
Genome Med. 2017 Mar 21;9(1):26
pubmed: 28327206
Mol Genet Metab. 2015 Dec;116(4):223-5
pubmed: 26596705
Orphanet J Rare Dis. 2017 Apr 11;12(1):68
pubmed: 28399928
Genet Med. 2014 Feb;16(2):176-82
pubmed: 23928913
Front Genet. 2019 Jan 21;9:723
pubmed: 30740127
N Engl J Med. 2013 Oct 17;369(16):1502-11
pubmed: 24088041